ERYTHROPOIETIC PROTOPORPHYRIA
Clinical trials for ERYTHROPOIETIC PROTOPORPHYRIA explained in plain language.
Never miss a new study
Get alerted when new ERYTHROPOIETIC PROTOPORPHYRIA trials appear
Sign up with your email to follow new studies for ERYTHROPOIETIC PROTOPORPHYRIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
EPP drug levels under the microscope: afamelanotide study completed
Disease control CompletedThis study looked at how the drug afamelanotide (Scenesse) behaves in the bodies of 28 people with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain on sun exposure. Researchers measured the drug's concentration in the blood after a single implant. The…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA
Phase: PHASE1, PHASE2 • Sponsor: Clinuvel Europe Limited • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Heartburn drug could ease painful sun sensitivity
Disease control CompletedThis Phase 2 trial tested whether oral cimetidine (Tagamet), a common heartburn drug, can reduce light sensitivity in people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These genetic conditions cause severe pain from sunlight exposure. The study en…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA
Phase: PHASE2 • Sponsor: Amy K. Dickey, M.D. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug offers hope for patients who Can't tolerate sunlight
Disease control CompletedThis study tested a drug called bitopertin in 75 adults with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain from sunlight exposure. The goal was to see if the drug is safe and can lower levels of a harmful substance in the blood. Participants receiv…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC